Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017)
Assembly Biosciences (ASMB) posted quarterly Current Deferred Tax Assets of $4.9 million for Q4 2017.
Analysis
Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017) Analysis & Trends
Assembly Biosciences' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $4.9 million for Q4 2017.
- In Q4 2017, Current Deferred Tax Assets changed N/A year-over-year to $4.9 million; the TTM figure through Dec 2017 stood at $4.9 million (changed N/A YoY), while the FY2017 annual figure was $4.9 million, changed N/A from the prior year.
- Current Deferred Tax Assets for Q4 2017 stood at $4.9 million.
- The five-year high for Current Deferred Tax Assets was $4.9 million in Q4 2017, with the low at $4.9 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Assembly Biosciences | 689.20 Mn | 368.83 Mn | - |